Tag: BB Biotech Ventures
Company News: Anergis Receives Swiss Life Sciences Prize
– Prestigious annual award under the patronage of the Swiss Biotech Association and BioValley Basel
– Sponsored by BB Biotech Ventures, Novartis Venture Fund and Venture Incubator
Anergis, a company focusing on proprietary allergy vaccines, today announced it has been awarded the Swiss Life Sciences Prize 2013. The prize, which has been granted for the tenth time in 2013, is under the patronage of the Swiss Biotech Association and BioValley Basel. Sponsors of the Swiss Life Sciences Prize are BB Biotech Ventures, Novartis Venture Fund and Venture Incubator. Jury members are Dr. Philippe Dro (CEO, GlycoVaxyn AG), Dr. Reinhard Glück (Former President, Swiss Biotech Association), Dr. Franz Saladin (Director, Chamber of Commerce of Basel), Dr. Dieter Scholer (Member, University Council, University of Basel), Dr. Matthias Staehelin (Head Life Sciences, VISCHER) and Jürg Zürcher (EMEIA Biotechnology Leader, Ernst & Young).